Scientific Program
| Ananta | Addala | USA | Solutions for equity: A call to action |
| Peter | Adolfsson | Sweden | Current use of connected pens |
| Stephanie | Amiel | UK | CGM detection of hypoglycemia in diabetes management |
| Lia | Bally | Switzerland | Virtual clinic for insulin therapy in type 2 diabetes |
| Katharine | Barnard-Kelly | UK | Consensus statement summary, navigating the maze of PROs |
| Tadej | Battelino | Slovenia | · CGM derived data on weekly insulins |
| · CGM derived criteria for stage 2 type 1 diabetes | |||
| Richard | Bergenstal | USA | We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia |
| Mithun | Bhartia | India | Diabetes and sex life – the role of technology to improve quality of life |
| Bruce | Bode | USA | Management of glucose in the hospital with AID systems |
| Stefan | Bornstein | Germany | Islet Transplantation 2024 |
| Emanuele | Bosi | Italy | Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool? |
| Charlotte | Boughton | UK | Cumulated experience with CamAPS in type 2 diabetes |
| Nataša | Bratina | Slovenia | Data on diabetes treatment in children below the age of six |
| Raffaella | Buzzetti | Italy | Antibody positivity in adult population |
| Anders | Carlson | USA | · The use of CGM in prediabetes and obesity |
| · Use of AID in patients with type 2 diabetes | |||
| Eda | Cengiz | USA | Update on diabetes Female Technology (femtech) |
| Antonio | Ceriello | Italy | Weight and glycemic variability: Bad companions for CVD development in diabetes |
| Manoj | Chawla | India | Optimizing real time CGM in self pay markets |
| Patrik | Choudhary | UK | Implication of HypoMETRICS for reporting hypoglycemia in clinical trials |
| Mark | Clements | USA | Just in time adaptive interventions: The new technology to “hack” diabetes self-management behavior |
| Xavier | Cos | Spain | Use of CGM by the primary care providers |
| Amy | Criego | USA | CGM Success: Device start and ongoing data management to improve patient care |
| Tali | Cukierman-Yaffe | Israel | · How to measure and monitor sarcopenia and frailty |
| · Diagnosis & monitoring of brain health in people with diabetes | |||
| Thomas | Danne | Germany | Worldwide progress achieving treatment targets in children with type 1 diabetes |
| Christophe | De Block | Belgium | Ketone continuous measurement – Is it needed? |
| Bastiaan | de Galan | The Netherlands | Impaired awareness of hypoglycemia |
| Sergio | di Molfetta | Italy | CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated |
| Klemen | Dovc | Slovenia | Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability |
| Celeste | Durnwold | USA | Can CGM replace the oral glucose tolerance test for diagnosis of Gestational diabetes? |
| Steven | Edelman | USA | · Top 10 tips to help people with diabetes (PwD) stay in range |
| · With Jeremy Pettus – Rapid fire interpretations of CGM downloads | |||
| Laya | Ekhlaspour | USA | Beyond carbohydrate counting: Optimizing mealtime insulin dosing |
| Tara | Ettestad | USA | CGM guided or personalized nutrition |
| Chiara | Fabris | USA | · What do women want (and need)? Results from the large-scale IMAGINE survey |
| · Simulation-enhanced closed-loop adaptation of long-acting insulin dosing in T2D | |||
| Leon | Farhy | USA | Diagnostic CGM |
| Andrea | Facchinetti | Italy | Digital twin technologies for treating diabetes |
| Deidre | Fitzgerald-Huges | Ireland | Shining a light on diabetic foot infections, development of novel photodynamic materials |
| Gregory | Forlenza | USA | Real-world data on hybrid closed-loop (HCL) in type 2 diabetes |
| Guido | Freckmann | Germany | International standard for evaluation of CGM systems: Approach of the IFCC |
| Juan | Frias | USA | Update on weekly insulin Efsitora |
| Satish | Garg | USA | Management options for treating obesity in type 1 diabetes patients |
| Michal | Gillon-Keren | Israel | Facilitate carb counting for people with diabetes |
| Francesco | Giorgino | Italy | Addressing glucose patterns in type 2 diabetes: Opportunities and challenges |
| Fernando | Gómez- Peralta | Spain | Connected insulin pens and caps: An expert’s recommendation from the area of diabetes of the Spanish Endocrinology and Nutrition Society (SEEN) |
| Amit | Gupta | India | Challenges and opportunities in digital diabetes care in India |
| Michael | Haller | USA | Cost effectiveness of immune therapies in preserving beta cell function – Real world applications |
| Simon | Heller | UK | Should the classification of hypoglycemia be updated? |
| Irl | Hirsch | USA | What has the GMI taught us about A1C? |
| Roman | Hovorka | UK | Fully closed-loop in type 1 and type 2 diabetes |
| Daria | Igudesman | USA | Diet, microbiome, obesity and type 1 diabetes |
| Peter | Jacobs | USA | Unannounced meal detection algorithms: Can we eliminate manual meal boluses? |
| Laura | Jacobsen | USA | Immune therapy – Predicting responders/non-responders |
| Andrej | Janež | Slovenia | Incretins and taste |
| Johan | Jendle | Sweden | Interoperability of diabetes technology – Regulatory hurdle |
| Morten H | Jensen | Denmark | Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project |
| Shashank | Joshi | India | Artificial intelligence in diabetes care |
| Partha | Kar | UK | Widening clinical use of diabetes tech in the UK |
| Neal | Kaufman | USA | The importance and impact of family caregivers on a variety of outcomes for people with diabetes |
| Jothydev | Kesavadev | India | 25 years of telemedicine Vs conventional care in diabetes: assessing vascular complications and quality of life |
| Kamlesh | Khunti | UK | Early intervention for type 2 diabetes in primary care |
| David | Klonoff | USA | Interoperability of diabetes technology – Academic view |
| Anna | Korsgaard Berg | Denmark | Skin problems caused by diabetes devices |
| Jernej | Kovac | Slovenia | Genetic background of obesity |
| Boris | Kovatchev | USA | Neural-Net artificial pancreas |
| Lori | Laffel | USA | Interventions to reduce health disparities in diabetes device use |
| Nebojsa | Lalic | Serbia | Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease |
| John | Leth | Denmark | The potential of open-source software in diabetes research |
| Alon | Liberman | Israel | Real world data from type 1 diabetes clinics |
| David | Maahs | USA | Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study |
| Julia | Mader | Austria | Lipohypertrophy and its effect on glucose control/insulin uptake/causes/detection/training and awareness of HCP and PwD |
| Roberto | Mallone | France | Benign autoimmunity & progression to type 1 diabetes |
| Marco | Marigliano | Italy | Relationships between insulin delivery system, CGM satisfaction and glucometrics |
| Brynn | Marks | USA | Insulin delivery is automated, but the education is not: Mothering diabetes technology users |
| Thomas | Martens | USA | CGM guided insulin management |
| Chantal | Mathieu | Belgium | CGM derived data on weekly insulins |
| Barbara | McGowan | UK | Medical therapies for treatment of obesity |
| Laurel | Messer | USA | Technology pearls for professionals |
| Nicola | Minuto | Italy | Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough |
| V | Mohan | India | Innovating to use existing technologies under resourced settings |
| Antoinette | Moran | USA | Impact of CGM in East Africa, research and translation |
| Helen | Murphy | UK | Should everyone with type 1 diabetes be offered closed-loop during pregnancy? |
| Mary | Murphy | UK | What inclusion of quality PRO assessment in clinical trials means to people with diabetes |
| Hamidah | Nabakka | Uganda | Diabetes advocate perspective on diabetes technology in low-income countries |
| Max | Nieuwdorp | The Netherlands | A balanced view on microbiome in obesity |
| Revital | Nimri | Israel | Maximizing glycemic control with automated insulin delivery in young children |
| Kirsten | Nørgaard | Denmark | · Low-dose glucagon to prevent hypoglycemia during exercise |
| · Effects of GLP1 in type 1 diabetes | |||
| Alexander | Olbrechts | Belgium | Interoperability of diabetes technology – A company’s view |
| Rakesh | Parikh | India | Artificial Intelligence in the management of diabetes |
| Anne | Peters | USA | Pod use for closed-loop in T2D |
| Jeremy | Pettus | USA | · With Steven Edelman – Rapid fire interpretations of CGM downloads |
| · Insulin resistance in type 1 diabetes: An underappreciated problem | |||
| Heiko | Peuscher | Germany | A survey on existing open-source projects in diabetes simulation |
| Moshe | Phillip | Israel | From dream to reality – The Automated Insulin Delivery (AID) system |
| Ivana | Rabbone | Italy | Technology in the changing management of diabetes in children |
| Dario | Rahelić | Croatia | Use of CGM in nutrition management in type 2 diabetes |
| Yves | Reznik | France | Closed-loop as home care for type 2 diabetes: The Close study |
| Michael | Rickels | USA | Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes |
| Camillo | Ricordi | USA | From the first-in-human success in stem cell derived Islet Transplantation to a cure for all patients with diabetes: Challenges, requirements, and possible solutions |
| Michael | Riddell | Canada | · CGM guided exercise |
| · Lessons learned from the ongoing type 1 diabetes exercise research Initiative | |||
| Samantha | Roberts | UK | Bringing science into lives: a NICE perspective |
| Teresa | Rodriguez-Calvo | Germany | Role of viruses in pathogenesis of type 1 diabetes |
| Leocadio | Rodríguez Mañas | Spain | Current treatment options for sarcopenia in the context of frail older people with diabetes |
| Julio | Rosenstock | USA | Update on weekly insulin Icodec: The way of the future |
| Banshi | Saboo | India | Welcome and introduction to Dtech symposium |
| Andrea | Scaramuzza | Italy | Real-world data in very young AHCL users – Comparison among different systems |
| Desmond | Schatz | USA | Enhancing our understanding of why type 1 diabetes develops. Lessons learned from organ donors |
| Oliver | Schnell | Germany | What PROs mean in routine clinical care |
| Eleanor | Scott | UK | CGM glucose trajectories associated with large and small for gestational age birthweight |
| Elisabeth | Selvin | USA | · Diabetes and cognitive decline and dementia |
| · Should A1C still be a diagnostic criterion for diabetes in 2024? | |||
| Viral | Shah | USA | GLP-1RA and SGLT in type 1 diabetes |
| Jennifer | Sherr | USA | Teplizumab therapy in the real world |
| Gregg | Simonson | USA | CGM (GMI/TIR) as diabetes quality metrics |
| Alan | Sinclair | UK | Sarcopenia in people living with diabetes |
| Jay | Skyler | USA | Stem cell approaches to type 1 diabetes |
| Darja | Šmigoc Schweiger | Slovenia | Guided management of diabetes in female |
| Tim | Street | UK | Interoperability of diabetes technology – Patient’s view |
| Stuart | Weinzimer | USA | Strategies to facilitate technology use in disadvantaged youth with diabetes |
| Emma | Wilmot | UK | Technology-supported behavior intervention in type 2 diabetes (STAND) |
| Jane | Yardley | Canada | Challenges of exercise in women with type 1 diabetes |
| Yariv | Yogev | Israel | Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation? |
| Dessi | Zaharieva | USA | Translation of exercise guidelines into practical applications for type 1 diabetes |
ATTD is the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes, assemble with the aim to be share knowledge and develop collaborations.
Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.
You are invited to explore the Scientific Program!
Interactive Program*Day by Day Schedule*Program Timetable*Program at a Glance*Interactive Program*Program Timetable
*Correct as of 17 February 2025
ATTD is the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes, assemble with the aim to be share knowledge and develop collaborations.
Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.
List of Confirmed Titles and Speakers
| Anastasia | Albanese-O’Neill | USA | General population screening – Successes and pitfalls |
| Grazia | Aleppo | USA | Automated multi-hormone delivery approach to manage postprandial glycemic excursion |
| Kamil | Armacky | UK | Together with Jazz Sethi: The benefits / disadvantages of social media in context of technology: The Diabfluencers |
| Lia | Bally | Switzerland | · The role of estradiol in energy and glucose-insulin homeostasis |
| · Perioperative closed-loop use during major surgery | |||
| Katharine | Barnard-Kelly | UK | · Spotlight-AQ – Harnessing AI to deliver the first step in the precision medicine pathway |
| · Human behaviors that lead to optimal uptake / reception of automation | |||
| Tadej | Battelino | Slovenia | Consensus on the use of CGM in individuals with type 2 diabetes |
| Roy | Beck | USA | Cost benefits of CGM use in type 2 diabetes |
| Riccardo | Bellazzi | Italy | Machine learning methods predicting diabetes complications |
| Natalie | Bellini | USA | Sex differences in diabetes management in the primary care setting |
| Katrien | Benhalima | Belgium | Use of the Medtronic 780G hybrid closed-loop system in type 1 diabetes pregnancy |
| Richard | Bergenstal | USA | Real world data on CGM in type 2 diabetes – Glucose control improvement |
| Cari | Berget | USA | Simplifying devices: Practical tips for the clinician working with AID |
| Barbara Murn | Berkopec | Slovenia | Periodic re-education for automated insulin delivery (AID) |
| Torben | Biester | Germany | 2024 ISPAD Guidelines chapter on insulin delivery: Automation now for a better future |
| Bruce | Bode | USA | Managing glucose in the hospital with CGM and AID |
| Stefan | Bornstein | Germany | New strategies for curative therapies for diabetes |
| Emanuele | Bosi | Italy | Screening of type 1 diabetes and celiac disease of the general pediatric population in Italy: Progress and preliminary results |
| Charlotte | Boughton | UK | Closed-loop from diagnosis – What have we learnt from longest-ever closed-loop study? |
| Nick | Cahm | UK | The power of the patient voice: The Libre saga |
| Giacomo | Cappon | Italy | Creating digital twins: Model-driven and AI methods – An introduction |
| Anders | Carlson | USA | · Time in tight glycemic range: Overview of the physiological data |
| · View, Counterview: Time in tight range should be the primary treatment goals and outcome measure in diabetes – View | |||
| Eda | Cengiz | USA | Leveraging technology to address gender differences in diabetes |
| Manoj | Chawla | India | Real-world data of CGM on GLP-1 usage |
| Pratik | Choudhary | UK | · Hypoglycemia and driving: Staying safe |
| · The individual impact of hypoglycemia on daily living: Lessons for personalization | |||
| Mark | Clements | USA | Remote patient health in pediatric diabetes care – Where are we today? |
| Rosa | Corcoy | Spain | Real world experience of hybrid closed-loop use during type 1 diabetes pregnancy: A Spanish perspective |
| Tali | Cukierman-Yaffe | Israel | Assessment of cognitive & physical health agility in the busy diabetes clinic – The why & the how |
| Colin | Dayan | UK | DEBATE: Adaptive trials in the Post-Teplizumab era: To placebo or not to placebo? Yes, we should continue with placebo |
| Christophe | De Block | Belgium | 90-minute aerobic exercise tests in people with type 1 diabetes using the 780G AID system. Examining timing of temporary target: The ACT-ONE study |
| Hans | DeVries | The Netherlands | Fully closed-loop – Bihormonal approaches |
| Klemen | Dovc | Slovenia | Planned versus spontaneous exercise in type 1 diabetes |
| Steven | Edelman | USA | DEBATE: Is there a real unmet need for continuous ketone monitoring? – CON |
| Dominic | Ehrmann | Germany | Objectively measured vs. subjective perceptions of glucose control: What is more important? |
| Laya | Ekhlaspour | USA | · Meal compositions and postprandial glycemic management in fully closed-loop systems |
| · NAP @ Home – First outpatient studies of Neural-net artificial pancreas | |||
| Anas | El Fathi | USA | · Digital twins, replay simulation, and decision support |
| · AI bolus calculator for people on multiple daily injections (MDI) | |||
| Juan | Espinoza | USA | Evidence and ideas from decision support systems on the user experience of automation |
| Chiara | Fabris | USA | · Glycemic excursion minimization (GEM): A lifestyle intervention for the management of type 2 diabetes |
| · Impact of sex on the control of type 2 diabetes | |||
| Rodolfo | Galindo | USA | Future of novel basal insulins |
| Satish | Garg | USA | · CGM use and effect on hospitalization and ER visits in type 2 diabetes |
| · Newer GLP analogs for treatment of obesity in type 1 diabetes | |||
| Samita | Garg | USA | Prevalence and rationale for new terminologies in NAFLD |
| Michal | Gillon-Keren | Israel | The role of nutrition management in people using automated insulin delivery systems |
| Francesco | Giorgino | Italy | Incretin-based therapies for the treatment of obesity-related diseases |
| Amit | Gupta | India | Intermittent use of CGM in type 2 diabetes |
| Michael | Haller | USA | · Inhaled insulin in pediatrics (INHALE-1 – Peds Study) |
| · Stages and monitoring in early type 1diabetes | |||
| Matthias | Hebrok | Germany | Optimizing stem cell derived beta cell function for transplantation |
| Tim | Heise | Germany | Oral and glucose-sensitive insulins: Will we ever have them? |
| Simon | Heller | UK | Is it possible to reserve awareness of hypoglycemia with AID technology? |
| Norbert | Hermanns | Germany | How to achieve a precision medicine approach using CGM and ecological momentary assessment |
| Julie | Heverly | USA | Time in tight glycemic range – A crucial goal or an unnecessary burden: PwD perspective |
| Irl | Hirsch | USA | · What’s new in pulmonary inhaled insulin? |
| · What are the appropriate glucose targets in the ICU? | |||
| · CGM-based intensification and de-intensification of therapy in type 2 diabetes | |||
| Korey | Hood | USA | Scoping out gaps in automation in the diabetes tech space |
| Roman | Hovorka | UK | How do I see the future of AID? |
| Sufyan | Hussain | UK | · How to use hybrid-closed-loop systems in complex outpatient clinical situations |
| · Fully closed-loop – Can people just do it? Insights from approaches using current commercial and open-source (DIY) HCL systems | |||
| Daria | Igudesman | USA | The role of nutrition in optimizing outcomes of GLP1/GIP |
| Peter | Jacobs | USA | AI-enabled meal detection and dosing in automated insulin delivery systems |
| Laura | Jacobsen | USA | DEBATE: Adaptive trials in the Post-Teplizumab era: To placebo or not to placebo? No, we should use only active (approved) control |
| Anna | Kahkoska | USA | · Use of technology to re-align treatment in individuals with type 2 diabetes in various living situations |
| · Use of CGM to improve the care of older insulin dependent individuals with cognitive / functional impairment | |||
| Partha | Kar | UK | The reality of the use of technology – Introduction |
| Karen | Kennedy | UK | With Eleanor Scott: Bringing science into lives: The Implementers |
| David | Kerr | USA | Time in tight glycemic range – A crucial goal or an unnecessary burden: Health inequalities perspective |
| Jothydev | Kesavadev | India | From insulin pumps to aid in India: Status of adoptability among people, physicians, and politicians |
| Tomasz | Klupa | Poland | Use of AID systems in order to improve the care of older individuals with type 1 diabetes & cognitive / functional impairment |
| Noriko | Kodani | Japan | PwD voices in designing new technology options for treating diabetes: The Diabetes Designer |
| Antje | Körner | Germany | A holistic approach to understanding childhood obesity |
| Primož | Kotnik | Slovenia | Therapy for monogenic obesity |
| Boris | Kovatchev | USA | · How digital twins can enhance clinical trials |
| · Machine learning – The key to fully automated closed-loop | |||
| Bernhard | Kulzer | Germany | AID, CSII & CGM: Real-world insights |
| Lori | Laffel | USA | · Is there ongoing need for telehealth? |
| · Use of GLP1 analogs in youth with type 1 diabetes for weight management in youth | |||
| · SGLT2i use in young people following approval by FDA and EMA in type 2 diabetes | |||
| Goos | Laverman | The Netherlands | Taking optimal advantage of diabetes technology: Potential role of a technical physician in your team |
| David | Maahs | USA | Remote patient monitoring, logistics and challenges for reimbursement |
| Julia | Mader | Austria | · Navigating the skies: Managing diabetes during air travel |
| · Trends of diabetes technology use in different European countries | |||
| Farid | Mahmud | Canada | Editorial perspectives and ISPAD type 2 diabetes chapter update |
| Marco | Marigliano | Italy | Cam APS Fx in very young children in Italy (2-year follow up) |
| Chantal | Mathieu | Belgium | · EDENT1FI: Towards general population screening in Europe |
| · Precision medicine in stage 2 type 1 diabetes | |||
| Jamie | Matu | UK | Advances in pharmacological interventions for pediatric and adolescent obesity – Current status and future prospects |
| Barbara | McGowan | UK | New horizons for treating obesity |
| Viswanathan | Mohan | India | Do different types of prediabetes require different types of prevention approaches? |
| Othmar | Moser | Germany | · The use of AID and exercise in type 1 diabetes: A position statement of the EASD and ISPAD |
| · Fully closed-loop: From announced to unannounced exercise | |||
| Clara | Mosquera-Lopez | USA | · AI analytics and CGM data science |
| · Using exercise data in combination of AI to help prevent nocturnal hypoglycemia | |||
| Marie | Mouler | Israel | Diabetes technology in competitive sports: The queen’s gambit |
| Medha | Munshi | USA | Use of technology to re-align treatment in individuals with type 1 diabetes in various living situations |
| Helen | Murphy | UK | The role of CamAPS FX in type 1 diabetes pregnancy |
| Joshua | Neumiller | USA | Triggers that indicate need for re-alignment in older adults with diabetes |
| Revital | Nimri | Israel | Decision support systems for healthcare providers and people with diabetes |
| Kirsten | Nørgaard | Denmark | · Can decision support for evaluating automated insulin delivery (AID) uploads assist clinicians? |
| · Status on Stenpool – An uploading program with access to all devices | |||
| Maria Cristina | Nostro | USA | Optimizing differentiation and engraftment of stem cell-derived islets for type 1 diabetes treatment |
| Tal | Oron | Israel | With Moshe Phillip: Update on ADIR (Antibody Detection Israeli Research) project |
| Naushira | Pandya | USA | Treatment of type 1 diabetes in long term care facilities |
| Rakesh | Parikh | India | Artificial intelligence (AI) in diabetes clinic: Expanding horizons |
| Ewan R | Pearson | UK | Heterogeneity of obesity and type 2 diabetes diabetes |
| John | Pemberton | UK | A paradigm shift: Using CGM to dose physical activity between meals to optimize time in range |
| Jeremy | Pettus | USA | View, Counterview: Time in tight range should be the primary treatment goals and outcome measure in diabetes – Counterview |
| Moshe | Phillip | Israel | With Tal Oron: Update on ADIR (Antibody Detection Israeli Research) project |
| Elizabeth | Pyatak | USA | Individual networks between glucose, mood, and daily functioning |
| Neesha | Ramchandani | USA | Giving your best shot: Focusing on safety, efficacy & comfort |
| Eric | Renard | France | · Fully closed-loop – Insulin only approaches |
| · Diabetes technology in different age groups | |||
| Michael | Rickels | USA | Different ways to detect unawareness |
| Michael | Riddell | Canada | Physical activity, technology and type 2 diabetes: Opportunities and challenges |
| Julio | Rosenstock | USA | · Should GLP-1 RAs be stopped prior to elective surgery? |
| · Triple agonist in type 2 diabetes | |||
| Donna H | Ryan | USA | Lessons from the SELECT trial: Rethinking the clinical applications for the GLP-1RA semaglutide |
| Victoria | Salem | UK | Biomaterials to aid beta cell replacement – Current and future perspectives |
| Andrea | Scaramuzza | Italy | Which are the best therapeutic strategies when exercising? Comparison among different AID systems |
| Desmond | Schatz | USA | Update on efforts to interdict type 1 diabetes |
| Eleanor | Scott | UK | With Karen Kennedy: Bringing science into lives: The Implementers |
| Jane Jeffrie | Seley | USA | Innovative models that support inpatient diabetes care & education |
| Jazz | Sethi | India | Together with Kamil Armacky: The benefits / disadvantages of social media in context of technology: The Diabfluencers |
| Viral | Shah | USA | Use of CGM in pre-type 2 diabetes |
| Anath | Shalev | USA | Novel type 1 diabetes therapies targeting endogenous islet cells |
| Shlomit | Shalitin | Israel | Prevalence of obesity in type 1 diabetes |
| Devorah | Shapiro | Israel | Growing bigger and independent – A structured educational program for patients aged 9 -12 who were diagnosed at a very young age |
| Jennifer | Sherr | USA | · Evidence and ideas from automated insulin delivery on the user experience of automation |
| · DEBATE: Is there a real unmet need for continuous ketone monitoring – PRO | |||
| Smadar | Shilo | Israel | Data-Driven approaches in endocrinology: From CGM to omics data |
| Galit | Shiovitch-Mantzuri | Israel | Follow-up of families with early detection of type 1 diabetes; The nurse perspective |
| Carmel | Smart | Australia | · Changing behaviors to manage weight in children and adolescents with type 1 diabetes |
| · Is carb counting enough? Optimizing mealtime insulin dosing | |||
| Darja | Šmigoc Schweiger | Slovenia | Sex differences in cardiovascular risk facture in youth with type 1 diabetes |
| Harald | Sourij | Austria | Exercise and long-acting insulins |
| Courtney | South | Canada | The impact of technology use on diabetes-related nutrition behaviors |
| Andrew F | Stewart | USA | Human beta cell regenerative drug therapy: A journey from impossible to possible |
| Jannet | Svensson | Denmark | Diabetes technology and sleep |
| Molly | Tanenbaum | USA | Time in tight glycemic range: A crucial goal or an unnecessary burden – Qualitative data perspective |
| Maria | Vasiloglou | Switzerland | Effectiveness of app-based interventions on diabetes and nutrition |
| Josep | Vehi | Spain | Applications of generative AI to diabetes |
| Deborah | Wake | UK | AI takes diabetes management beyond AID |
| Emma | Wilmot | UK | What do people with diabetes expect from diabetes technology? |
| Yariv | Yogev | Israel | How do you know that your pregnant woman with diabetes is well controlled? |